drugset
drugset / Trial / NCT00003492

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

NCT00003492 ↗

Phase 2 Terminated 9 enrolled Burzynski Research Institute
NaSingle-groupOpen-labelTreatment

Summary

Current therapies for Stage IV Lung Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV Pancreatic Cancer. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stage IV Lung Cancer.

Timeline

Start
1996-04-10
Primary completion
2000-12-01
Completion
2000-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Astugenal Unknown — Intravenous
Subject antineoplaston A10 Small molecule — Intravenous

Indications

No indication recorded.